This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

TherapeuticsMD, Inc. Launches Its First Prescription Prenatal Vitamin On March 1, 2012

Stocks in this article: TXMD

TherapeuticsMD™, Inc. ("Therapeutics™" or the "Company") (OCTQB: TXMD), parent company of vitaMedMD, LLC ("vitaMedMD™"), a specialty pharmaceutical company, announced today that on March 1, 2012 it will launch its first prescription prenatal vitamin, vitaMedMD™ Plus Rx . vitaMedMD™ Plus Rx is a single-dose combo-pack containing one prenatal vitamin tablet and one life’s DHA™ capsule. The Company plans to launch its second prenatal vitamin, vitaMedMD™ One Rx in April 2012 which will combine the prenatal vitamin and a smaller amount of life’s DHA™ into a single-dose capsule.

Robert Finizio, Chief Executive Officer of the Company, stated, "We are very excited to introduce vitaMedMD™ Plus Rx as our first prescription-only prenatal vitamin to be sold nationwide. We believe our unique formulation of vitaMedMD™ Plus Rx will be warmly welcomed by physicians and patients and will be seen as a necessary step to ensure a healthy pregnancy. Although we have been in the prenatal vitamin market for over 3 years, our upcoming prescription products are aimed at meeting the product expansion requests from our current customer base of physicians, payors and patients. We look forward to the continued expansion of our product portfolio of high quality, safe, innovative market-leading women’s healthcare prescription products."

About TherapeuticsMD™, Inc.

TherapeuticsMD™ is the parent company of vitaMedMD™, a specialty pharmaceutical company. vitaMedMD™ specializes in delivering the highest quality of products for women's health needs through its national sales force and its website. vitaMedMD™ has also developed a patent-pending technology and business methodology to market over-the-counter and prescription versions of nutritional supplements, drugs, medical foods and other medical products directly to consumers with the recommendation of their physician. vitaMedMD’s™ business model creates unique value propositions for patients, physician/providers and insurance payors. vitaMedMD™ offers superior-quality products often for a lower overall cost to patients and payors while increasing efficiencies for physicians. vitaMedMD’s™ technology allows it to collect and analyze data from various sources to improve patient compliance and education, facilitate product development and provide immediate feedback on effectiveness of therapies. The result is increased efficiency and communication between the patient, physician/provider and insurance payor, ultimately creating improved outcomes for all. This combination of efficient distribution and technology provides measurable customer benefits differentiating vitaMedMD™ from existing competitors in the market. Questions may be directed to Daniel A. Cartwright, Chief Financial Officer, at (561) 961-1911. More information on TherapeuticsMD™ is available on its website at More information on vitaMedMD™ and its products is available on its website at

This press release shall not constitute an offer to sell or a solicitation of an offer to buy securities of TherapeuticsMD, Inc. Certain statements in this release and other written or oral statements made by or on behalf of the Company are “forward-looking statements” within the meaning of the federal securities laws. Statements regarding future events and developments and our future performance, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. The forward-looking statements are subject to a number of risks and uncertainties including market acceptance of the Company’s services and projects and the Company’s continued access to capital and other risks and uncertainties. The actual results the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. These statements are based on our current expectations and speak only as of the date of such statements. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of future events, new information or otherwise.

Copyright Business Wire 2010

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs